$ZBH

BMO Capital reiterated a Market Perform rating and $96 price target for Zimmer Biomet (ZBH) due to its iodine-coated hip implant opportunity in Japan, estimating a $72M steady-state opportunity. ZBH shares trade at $91.05, below the target. The company reported strong Q2 2026 earnings, exceeding expectations, with adjusted EPS of $2.07 and revenue of $2.18B. The firm's U.S. salesforce overhaul is progressing well, contributing to its positive outlook.

Thornal Kevin R (Grp Pres-Global Business) sold 5,691 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at $92.95 ($0.53M total) on 2026-09-11.

Phipps Chad F (See remarks below.) sold 3,000 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at $98.35 ($0.30M total) on 2026-09-04.

ZIMMER BIOMET HOLDINGS, INC. (ZBH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas

Zimmer Biomet Holdings (ZBH) announced a third-quarter 2026 cash dividend of $0.24 per share. The company's stock is trading at $100.04, with recent gains of 19.45% over 90 days and 6.50% over 30 days, but longer-term returns are down 4.72% over one year and 26.62% over five years. Analysts suggest the stock is 7% undervalued, with a fair value estimate of $107.57, citing growth in digital health and robotics. However, the company faces pricing pressures and integration challenges from recent ac

Zimmer Biomet (ZBH) reported Q2 results on Aug. 5, with adjusted EPS of $2.07 vs $2.01 expected and revenue of $2.2B vs $2.1B forecast. The company guided full-year adjusted EPS to $8.47-$8.59. Analysts covering ZBH have a Hold consensus, with a mean price target of $104.67 and a Street-high of $125.

Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.

Bernstein raised its price target on Zimmer Biomet to $93 from $91, according to the report. The article also notes a separate Jefferies price target change to $105 from $95. Investors may use these analyst updates as inputs for valuation and expectations for the stock.

Zimmer Biomet reported Q2 revenue of about $2.18bn, up 4.8% YoY. Knees led at $828.9m, followed by S.E.T. at $586m and hips at $562.7m. The company raised its 2026 revenue growth outlook to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59 per diluted share. Shares rose over 5% to about $101 at the open.

Zimmer Biomet (ZBH) reported Q2 2026 adjusted EPS of $2.07, above the $2.01 consensus, and net sales of $2.18B, above the $2.13B estimate. GAAP EPS was $1.03. The company raised 2026 guidance, including revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares rose 1.4% pre-market.